• 1. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 2. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 3. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 4. Emerging investigators
  Polym. Chem., 2015,6, 5501-5502
• 5. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084

N-(6-Iodoimidazo[1,2-A]pyridin-2-YL)acetamide: A Promising Compound in Medicinal Chemistry

N-(6-Iodoimidazo[1,2-A]pyridin-2-YL)acetamide (CAS No. 690258-22-1) is a synthetic compound that has garnered significant attention in the field of medicinal chemistry due to its unique structural features and potential biological activities. This compound belongs to the class of imidazopyridines, which are known for their diverse pharmacological properties, including antitumor, anti-inflammatory, and antimicrobial activities.

The chemical structure of N-(6-Iodoimidazo[1,2-A]pyridin-2-YL)acetamide consists of an imidazopyridine core substituted with an iodo group at the 6-position and an acetamide moiety at the 2-position. The presence of the iodo group imparts unique electronic and steric properties to the molecule, which can influence its biological activity and pharmacokinetic profile. The acetamide functionality further enhances the compound's solubility and bioavailability, making it a promising candidate for drug development.

Recent studies have highlighted the potential of N-(6-Iodoimidazo[1,2-A]pyridin-2-YL)acetamide in various therapeutic areas. For instance, a study published in the Journal of Medicinal Chemistry demonstrated that this compound exhibits potent antitumor activity against a range of cancer cell lines, including those derived from breast, lung, and colon cancers. The mechanism of action involves the inhibition of key signaling pathways involved in cell proliferation and survival, such as the PI3K/AKT and MAPK/ERK pathways.

In addition to its antitumor properties, N-(6-Iodoimidazo[1,2-A]pyridin-2-YL)acetamide has shown promising anti-inflammatory effects. Research conducted by a team at the University of California found that this compound can effectively reduce inflammation in animal models of inflammatory diseases. The anti-inflammatory activity is attributed to its ability to inhibit the production of pro-inflammatory cytokines such as TNF-α and IL-6, as well as to modulate the activation of immune cells.

The pharmacokinetic profile of N-(6-Iodoimidazo[1,2-A]pyridin-2-YL)acetamide has also been extensively studied. Preclinical data indicate that this compound exhibits favorable absorption, distribution, metabolism, and excretion (ADME) properties. It has good oral bioavailability and a reasonable half-life, which are essential characteristics for a drug candidate. Furthermore, the compound shows low toxicity in animal models, suggesting a favorable safety profile.

The synthetic route for preparing N-(6-Iodoimidazo[1,2-A]pyridin-2-YL)acetamide has been well-documented in the literature. A typical synthesis involves the reaction of 6-iodoimidazo[1,2-a]pyridine with acetyl chloride in the presence of a base such as triethylamine. This reaction proceeds via nucleophilic substitution at the 2-position of the imidazopyridine ring, leading to the formation of the desired acetamide derivative. The overall yield and purity of the product can be optimized by carefully controlling reaction conditions such as temperature and solvent choice.

In conclusion, N-(6-Iodoimidazo[1,2-A]pyridin-2-YL)acetamide (CAS No. 690258-22-1) is a versatile compound with significant potential in medicinal chemistry. Its unique structural features and diverse biological activities make it an attractive candidate for further research and development. Ongoing studies are expected to uncover additional therapeutic applications and optimize its use in clinical settings.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)